# US 2022/0064319 A1 · Human monoclonal antibody human cd134 (ox40) and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064319 A1
- Document ID: US20220064319A1
- Status: Published application
- Kind: A1
- Application number: 17/525,512
- Filed: 2021-11-12
- Published: 2022-03-03
- Earliest claimed: 2005-11-25
- Assignees: Kyowa Kirin Co., Ltd.
- Applicants: Kyowa Kirin Co., Ltd.
- Inventors: Shinichiro KATO; Rachel SOLOFF NUGENT; Hitoshi YOSHIDA; Michael CROFT
- Web page: https://patentgrep.com/patent/US20220064319A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 2039/505: {comprising antibodies}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/21: from primates, e.g. man
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 2799/026: where the vector is derived from a baculovirus
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.

## Claims

### Claim 1

An isolated or purified monoclonal antibody, or a fragment thereof, that specifically binds to an epitope in an amino acid sequence OX40 extracellular domain, wherein the antibody comprises: a heavy chain variable region comprising an amino acid sequence from the amino acid at position 20 of SEQ ID NO:9 to the amino acid at position 136 of SEQ ID NO:9, and a light chain variable region comprising an amino acid sequence from the amino acid at position 21 of SEQ ID NO:10 to the amino acid at position 127 of SEQ ID NO:10.

### Claim 2 (depends on 1)

The fragment of the monoclonal antibody of claim 1, wherein the fragment is selected from Fab, Fab′, F(ab′)2, Fv, Fd, single-chain Fvs (scFv), or disulfide-linked Fvs (sdFv).

### Claim 3 (depends on 1)

The monoclonal antibody or, the fragment thereof, of claim 1, wherein the OX40 is human OX40.

### Claim 4 (depends on 1, 2, 3)

The monoclonal antibody or, the fragment thereof, of any one of claims 1-3, wherein the OX40 comprises a sequence:
(SEQ ID NO: 50)
MCVGARRLGRGPCAALLLLGLGLSTVTGLHCVGDTYPSNDRCCHECRPG
NGMVSRCSRSQNTVCRPCGPGFYNDVVSSKPCKPCTWCNLRSGSERKQL
CTATQDTVCRCRAGTQPLDSYKPGVDCAPCPPGHFSPGDNQACKPWTNC
TLAGKHTLQPASNSSDAICEDRDPPATQPQETQGPPARPITVQPTEAWP
RTSQGPSTRPVEVPGGRAVAAILGLGLVLGLLGPLAILLALYLLRRDQR
LPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI.

### Claim 5 (depends on 1, 2, 3)

The monoclonal antibody or, the fragment thereof, of any one of claims 1-3, wherein the antibody is an IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD isotype.

### Claim 6 (depends on 1, 2, 3, 4)

The monoclonal antibody or, the fragment thereof, of any one of claims 1-3 and 4, wherein the antibody or subsequence further comprises a heterologous domain.

### Claim 7 (depends on 1, 2, 3)

A pharmaceutical composition comprising the monoclonal antibody or, the fragment thereof, of any one of claims 1-3, and a pharmaceutically acceptable carrier or excipient.

### Claim 8 (depends on 1, 2, 3)

The monoclonal antibody, or the fragment thereof, any one of claims 1-3, wherein the antibody comprises a human, humanized or chimeric antibody.

### Claim 9 (depends on 1, 2, 3)

The monoclonal antibody, or the fragment thereof, any one of claims 1-3, wherein the antibody has OX40 antagonist activity.
